Trial Profile
An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2009
Price :
$35
*
At a glance
- Drugs Troxacitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 16 Jan 2008 Status changed from in progress to discontinued.
- 29 Aug 2005 New trial record.